Prevduo (Glycopyrrolate/Neostigmine) Patent Expiration, LOE Window & CMS Spending

Prevduo (Glycopyrrolate/Neostigmine) by Endo Pharmaceuticals: FDA Orange Book LOE 2038-10-25, 0 AB generics, $37K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayN216903 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-10-25
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$37K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$37K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel